other material
confidence high
sentiment positive
materiality 0.75
Entera Bio-OPKO collaboration: oral GLP-1/glucagon tablet, $8M equity investment
Entera Bio Ltd.
- OPKO purchased 3,685,226 Entera shares at ~$2.17/share ($8M) to fund Entera's 40% development cost share through Phase 1.
- Profit/cost split initially 60% OPKO / 40% Entera; opt-out after Phase 1 yields 85%/15% with OPKO funding.
- Parties expect to file IND with FDA later in 2025 for oral tablet combining OPK-88006 and Entera's N-Tab™ technology.
- OPKO subject to 12-month lockup on shares and 24-month standstill on acquiring additional Entera equity.
- Preclinical data reported September 2024 showed favorable pharmacodynamic and pharmacokinetic profiles.